NFE2L2 and breast carcinoma: Echinomycin A is an active compound extracted from Ligusticum wallichii, which can disrupt mitochondrial structure and function in breast cancer cells, enhance ROS-induced ferroptosis in TNBC cells through activation of the Nrf2/HO-1 signaling pathway, and could be a potential lead compound for breast cancer treatment (124).